礼来公司的口服GLP-1受体激动剂Foundayo(奥格列酮)在三项关键的Type 2 diabetes试验中均展现出更优的糖化血红蛋白A1C控制和体重减轻效果。
印第安纳波利斯,2026年6月8日/PRNewswire/ -- Zepbound(替拉帕肽)的生产商礼来公司(纽约证券交易所代码:LLY)今日公布了ACHIEVE项目中三项3期临床试验的详细结果,这些试验旨在评估小分子药物Foundayo(奥福格列隆)……
该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Produk Berkaitan Artikel Ini
Produk ini dipadankan secara automatik berdasarkan tajuk, ringkasan, dan kandungan artikel.
Soalan Lazim
Which products are related to this article?
The system matched these relevant products from the article content: Rybelsus semaglutide (Tablet Semaglutide) 7mg 100 tablet (versi Jepun) – Beli dalam talian Lucius Ceritinib – Beli Dalam Talian Lucius Trelagliptin – Beli dalam talian Lucius Aprocitentan – Beli dalam talian.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.